Lovastatin

HEL cells were provided by Dr. Yasushi Kawaguchi in the Division of Molecular Virology, Department of Microbiology and Immunology, at the Institute of Medical Science, the University of Tokyo, Tokyo, Japan. The mouse mammary cancer cell line FM3A was provided by Dr. Fumio Hanaoka at the Institute for Biomolecular Science, Faculty of Science, Gakushuin University, Tokyo, Japan. An inhibitor kit containing 323 chemicals was provided by the Screening Committee of Anticancer Drugs (director; Dr. Takao Yamori). Paclitaxel, docetaxel, thapsigargin, cisplatin, cycloheximide, cytochalasin D, lovastatin, camptothecin, aphidicolin, and nocodazole were purchased from Wako Pure Chemical Industries (Osaka, Japan). Hydroxyurea was purchased from Nacalai Tesque (Kyoto Japan). SB225002 and radicicol were purchased from Calbiochem, San Diego, CA, USA. Bortezomib was purchased from Selleck Chemicals, Houston, TX, USA. As reagents for cell culture, Dulbecco's Modified Eagle's medium (DMEM), fetal bovine serum (FBS), and 0.25% Trypsin/EDTA solution were purchased from Nacalai Tesque, Hyclone (Logan, UT), and Sigma-Aldrich (St. Louis, MO, USA), respectively.